Marchi, Enrica
- University of Virginia · Internal Medicine (NIH department code)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
FY2022 NIH rank #12,635
- R01 Holder
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2020 through FY2022Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award categories
- Internal Medicine
NIH Funding · FY2022
Linked Award Amount
$808.2K
Full award amounts, FY2022
Award Records
1
Records listing this PI
Award-Linked Rank
#12,635
By linked amount among FY2022 PIs
Earliest Year Loaded
2020
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2022 award records by amount
NIH award records listing Marchi, Enrica as a PI. Multi-PI records show the full award amount for context.
- 5R01FD006814-02R01Contact PIA Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).University of Virginia · Internal Medicine (NIH department code)$808.2Kaward amount
Award organization
Organizations that administered FY2022 awards listing Marchi, Enrica as a PI.
FY2022 award administered by University of Virginia (VA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2020First NIH AwardUniversity of Virginia
- 2020$500K Cumulative Funding
- 2020Entered Top 50% NationallyRanked #4236
- 2020Entered Top 25% NationallyRanked #4236
- 2020R01 Grant Holder
- 2022$1M Cumulative Funding